Life Sciences Venture Capital Monitor - Europe 03/2023 published - FCF Fox Corporate Finance GmbH

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 03/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of March 2023 we identify the following current VC trends in Europe:

• In 2023, overall Life Sciences funding has reached EUR 1,745m
• Top 5 Deals exceed EUR 50m each, largest transaction amounted to EUR 130m in Amolyt Pharma (France)
• European Innovation Council Fund (Belgium) dominates the Top 5 Investors (by deal volume), followed by Flerie Invest (Sweden) and Novo Holdings (Denmark)
• Biotech received 50% of the total investment volume (-6 compare to the previous month)
• Central Nervous System dominates as the top indication in Biotechnology

To access the full report, please click here.